NBIX
NEUROCRINE BIOSCIENCES INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- May 22 Bernstein initiates
- Jul 10 ▼ 1 insider sell $790.5K at $181.02
- Jul 28 ▼ 1 insider sell $227.5K at $182.01
- Sep 9 to Sep 14 ▼ 2 days of insider sells: $826.4K by 3 insiders, avg $156.18
- Sep 30 ▲ 4 funds open new positions (13F)
- Oct 30 to Nov 3 ▼ 3 days of insider sells: $2.3M by 1 insider, avg $155.73
- Nov 2 ▲ Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up…
- Nov 2 ▲ Earnings: NBIX Q3 2026 Earnings: EPS $3.29 (+68.9% vs est)
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $4.2M.
- InstitutionsBULLISH
Q3 2026: 55 added (4 new), 32 trimmed or exited. Largest new: Jupiter Asset Management $35.7M.
- AnalystsBULLISH
32 of 37 rate it Buy or better.
- Short sellersSTEADY
Short interest −8.5% to 5.90M shares. 5.4 days to cover, ≈5.8% of shares.
- TrendUPTREND
11% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VICTORY CAPITAL MANAGEMENT INC | ADD | $118.7M |
| Aberdeen Group plc | DOUBLED | $112.8M |
| Ninety One UK Ltd | DOUBLED | $61.7M |
| BARCLAYS PLC | ADD | $58.4M |
| Candriam S.C.A. | ADD | $49.1M |
| Zurcher Kantonalbank (Zurich Cantonalbank) | DOUBLED | $48.6M |
| CITIGROUP INC | ADD | $41.8M |
| JUPITER ASSET MANAGEMENT LTD | NEW | $35.7M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
37 analysts| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 4, 2026 | Guggenheim MAINTAIN | Buy |
| Nov 3, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 3, 2026 | RBC Capital MAINTAIN | Outperform |
| Nov 3, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Nov 3, 2026 | Piper Sandler MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
ROBERTS EIRY Chief Medical Officer Nov 4, 2026 | AWARD | 8,314 sh |
ROBERTS EIRY Chief Medical Officer Nov 4, 2026 | AWARD | 1,506 sh |
MORROW GEORGE J Director Nov 3, 2026 | EXERCISE | $386.2K |
MORROW GEORGE J Director Nov 3, 2026 | SELL | $15.8K |
MORROW GEORGE J Director Nov 3, 2026 | SELL | $16.2K |
MORROW GEORGE J Director Nov 3, 2026 | SELL | $98.2K |
MORROW GEORGE J Director Nov 3, 2026 | SELL | $202.0K |
MORROW GEORGE J Director Nov 3, 2026 | SELL | $150.5K |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Washington
Short side
FINRA· Oct 30, 2026SecBot reports
30 filings · 5 bullish · 1 bearish · 1 mixed · 23 neutral- NEUTRAL 144Nov 10, 2026
Sanjay Keswani, a former affiliate of Neurocrine Biosciences, filed a Form 144 notice of intent to…
The filing is a routine advance notice of a planned sale by a former affiliate, not a current executive or board member. The sale is small relative to market cap and appears to be a standard…
- NEUTRAL PTAB-TRIALNov 10, 2026
The PTAB granted institution of post-grant review (PGR2026-00061) on Neurocrine's petition…
Monitor the trial schedule and any related district-court or ITC litigation that may be stayed or affected. The final written decision will determine whether claims are cancelled, which could impact…
- NEUTRAL PTAB-TRIALNov 10, 2026
The PTAB granted institution of post-grant review (PGR2026-00059) on Neurocrine's petition…
Monitor the PTAB trial schedule and any related district-court or ITC litigation the decision may reference in future filings. The final written decision will determine whether the challenged claims…
- NEUTRAL PTAB-TRIALNov 10, 2026
The PTAB granted institution of a post-grant review (PGR2026-00060) on Neurocrine Biosciences'…
Monitor the PTAB docket for the final written decision, expected within about 12 months. The outcome could affect Neurocrine's competitive positioning in adrenal rest tumor therapies if the patent…
All NBIX filing & press-release reports (30)
- 144 reportNov 10, 2026
- PTAB-TRIAL reportNov 10, 2026
- PTAB-TRIAL reportNov 10, 2026
- PTAB-TRIAL reportNov 10, 2026
- PRESS-RELEASE reportNov 2, 2026
- 144 reportNov 2, 2026
- 8-K reportNov 2, 2026
- 144 reportOct 30, 2026
- SC 13G reportOct 30, 2026
- INST-CLUSTER reportOct 27, 2026
- SC 13G/A reportOct 15, 2026
- INST-CLUSTER reportOct 15, 2026
- 3 reportOct 7, 2026
- CLUSTER reportSep 15, 2026
- CLUSTER reportJul 13, 2026
- PRESS-RELEASE reportJul 9, 2026
- CLUSTER reportJun 9, 2026
- CLUSTER reportJun 8, 2026
- CLUSTER reportJun 8, 2026
- CLUSTER reportJun 4, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportJun 2, 2026
- CLUSTER reportMay 29, 2026
- CLUSTER reportMay 28, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 21, 2026
- CLUSTER reportMay 18, 2026
- 8-K reportMay 18, 2026
- 8-K reportApr 6, 2026